UPPSALA, Sweden, April 27 /CNW/ - Beactica, the leading Swedish
fragment-based drug discovery company, today announced that it has
entered into an agreement with Janssen Research & Development, a
division of Janssen Pharmaceutica NV. Under the agreement, Beactica
will use its proprietary drug discovery platform, SprintTM, to generate small-molecule lead compounds against undisclosed targets
of therapeutic interest to Janssen. Financial terms of the agreement
were not disclosed.
"We are pleased to work with Janssen and look forward to utilising
Beactica's platform to support the progress of one of their prioritized
programmes" said Beactica CEO, Dr Per Kallblad. "Fragment-based
approaches to drug discovery are creating new pathways towards
small-molecule leads of high-quality and Beactica has worked hard to
win a reputation for being at the cutting-edge of advances".
Janssen is the fourth global top-20 pharmaceutical company to enter into
an agreement with Beactica in the past 18 months.
Beactica AB is a specialist drug discovery company, utilising its
proprietary methodologies to evaluate the biophysical interaction of
molecules in order to generate novel therapeutics. The Company offers
expertise and services in the area of surface plasmon resonance (SPR)
biosensor-based small molecule interaction analysis and partnerships
for fragment-based lead generation using its proprietary Sprint(TM)
platform. Founded in 2006 based on research carried out at Uppsala
University and first-hand experience from the drug discovery industry,
Beactica has established a robust reputation as the leader in SPR-based
small molecule drug discovery. As well as providing services and
building collaborations with external companies, Beactica is
progressing its own drug discovery programmes. The company has its
headquarter in Uppsala, Sweden. For more information, please visit http://www.beactica.com.
SOURCE Beactica AB
For further information:
Dr Per Kallblad, Beactica CEO, +46-18-56-08-80